Ehave, Inc. (OTCQB: EHVVF), a healthcare company dedicated to empowering the mental health community with next-generation digital solutions, today voiced its support for the millions of millions of adults, families, and children worldwide living with Attention Deficit Hyperactivity Disorder in advance of ADHD Awareness Month in October.
ADHD is a prevalent condition, affecting 7% of children under 17 and 4% of adults, and has been well-studied since the condition was first described. Today, there are many effective treatments for ADHD but the pace of innovation in assessment, treatment and outcomes verification have not kept pace with new tools available.
Ehave has partnered with the Hospital for Sick Children in Toronto in the development of MegaSonic Action Dash and MegaSonic Danger Dive, a suite of engaging video games with embedded cognitive assessment and rehabilitation tasks that are built on established methodologies for the measurement of cognitive abilities in populations with ADHD, though they do not yet have regulatory clearance for diagnostic or therapeutic use. As recently reported, Ehave intends to launch these smartphone-based video games, previously only available through a physician, to the public. Their work in this area has been featured in a recent Canadian documentary about adults struggling with ADHD.
“Following clearance by the U.S. Food and Drug Administration and Health Canada, these games could potentially help physicians more easily diagnose and track treatment of kids with ADHD,” Prateek Dwivedi, President and CEO of Ehave said. “Methodologies commonly used today involve repetitive performance of tasks using a digital interface. Research has found that patients have difficulty completing the necessary regimen of tasks due to lack of engagement. By leveraging technology to provide a tool that has the attractions of a retro smartphone game, our products have been developed to address these primary concerns as well as to enable a breadth of cognitive processes/abilities to be assessed and an individualized cognitive rehabilitation program to be administered remotely.”
Ehave is empowering the mental healthcare community with a next-generation of data-rich tools designed to improve patient management, diagnosis and treatment. With Ehave Connect, Ehave’s mental health informatics platform, clinicians can make objective, data-driven decisions while keeping patients informed and engaged throughout their mental healthcare journey. Ehave Connect offers a powerful set of core features that integrate with a growing selection of tools and applications developed by Ehave and its leading partners, including Multi-Health Systems (“MHS”), a leading publisher of psychological assessments. Ehave is initially focused on improving the standard of care in attention deficit hyperactivity disorder (“ADHD”), through its collaboration with the Hospital for Sick Children (“SickKids”). Ehave Connect is also being utilized to advance the validation and optimization of medical cannabis, through its collaboration with MedReleaf.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading “Risk Factors” in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC’s website, http://www.sec.gov